艾司西酞普兰与阿戈美拉汀联合厄贝沙坦氢氯噻嗪治疗抑郁症合并高血压的疗效OA
Efficacy of Escitalopram and Agomelatine Combined with Irbesartan Hydrochlorothiazide in the Treatment of Depression Complicated with Hypertension
目的 探讨艾司西酞普兰、阿戈美拉汀联合厄贝沙坦氢氯噻嗪治疗抑郁症合并高血压的疗效.方法 选取北京市昌平区中西医结合医院2020年2月至2022年3月收治的100例抑郁症合并高血压患者作为研究对象,采用随机数字表法分为试验组(n=50)与对照组(n=50).两组均使用厄贝沙坦氢氯噻嗪进行降血压治疗,同时对照组使用艾司西酞普兰进行抗抑郁治疗,试验组使用艾司西酞普兰联合阿戈美拉汀进行抗抑郁治疗.分别在治疗前后应用汉密尔顿抑郁量表(HAMD)评价患者抑郁情况,应用负性认知加工偏向问卷(NCPBQ)评价患者负性认知情况,比较两组患者治疗前后 5-羟色胺(5-HT)、脑源性神经营养因子(BDNF)水平及副反应量表(TESS)评分、不良反应发生率.结果 治疗后两组HAMD、NCPBQ评分降低,且试验组低于对照组,差异有统计学意义(P＜0.05);治疗后两组 5-HT、BDNF 水平升高,且试验组高于对照组,差异有统计学意义(P＜0.05);治疗 4 周后、8 周后,试验组TESS评分较对照组低,但差异无统计学意义(P＞0.05);试验组不良反应发生率与对照组比较,差异无统计学意义(P＞0.05).结论 艾司西酞普兰、阿戈美拉汀联合厄贝沙坦氢氯噻嗪治疗抑郁症合并高血压可进一步降低患者血压水平,减轻抑郁程度与负性认知情况,调节血清5-HT、BDNF表达水平,且安全性较高.
Objective To explore the efficacy of Escitalopram,Agomelatine combined with irbesartan hydrochlorothiazide in the treatment of depression complicated with hypertension.Methods A total of 100 patients with depression combined with hypertension admitted to Beijing Changping District Hospital of Integrated Traditional Chinese and Western Medicine from February 2020 to March 2022 were selected as the study objects,and were divided into experimental group(n=50)and control group(n=50)by random number table method.Both groups were treated with irbesartan hydrochlorothiazide to reduce blood pressure,while the control group was treated with escitalopram for antidepressant treatment,and the experimental group was treated with escitalopram combined with agomelatine for antidepressant treatment.Hamilton Depression Scale(HAMD)was used to evaluate patients'depression before and after treatment,and negative cognitive Processing Bias Questionnaire(NCPBQ)was used to evaluate patients'negative cognition.The levels of 5-hydroxytryptamine(5-HT),brain-derived neurotrophic factor(BDNF)before and after treatment,TESS score and incidence of adverse reactions were compared between the two groups.Results After treatment,HAMD and NCPBQ scores of the two groups were decreased,and the test group was lower than the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of 5-HT and BDNF of the two groups were increased,and the test group were higher than those in control group,and the difference was statistically significant(P＜0.05).After 4 and 8 weeks of treatment,TESS scores of experimental groups were lower than those of control group,but the difference was not statistically significant(P＞0.05).There was no significant difference in the incidence of adverse reactions between experimental group and control group(P＞0.05).Conclusion Escitalopram,agomelatine combined with irbesartan hydrochlorothiazide in the treatment of depression complicated with hypertension can further reduce the blood pressure level,reduce the degree of depression and negative cognition,and regulate the expression levels of serum 5-HT and BDNF,with high safety.
柏林;王阳
北京市昌平区中西医结合医院精神科,北京 102208
药学
艾司西酞普兰阿戈美拉汀厄贝沙坦氢氯噻嗪抑郁症高血压疗效安全性
CitalopramAgomelatineIrbesartan hydrochlorothiazideDepressionHypertensionCurative effectSecurity
《中国药物经济学》 2024 (005)
42-45,50 / 5
评论